What bothered me most was the increase in staff costs from $500,000 the previous quarter to now $700,000. I have emailed the investor relations person with a few questions - that is, is it extra sales staff. If anything useful comes back, I will post.
Before Osteopore products can be sold on the Chinese mainland, they have to pass trials, so probably a couple of years.
Ann: Activities Update Qtr Ending March 2023 and Appendix 4C, page-7
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
